2023 World Conference on Lung Cancer (Posters)-P2.06. The Safety and Efficacy of Durvalumab as 1st Line Therapy in Patients with Advanced NSCLC and ECOG PS of 2

P2.06. The Safety and Efficacy of Durvalumab as 1st Line Therapy in Patients with Advanced NSCLC and ECOG PS of 2 - PDF(Slides)

Back to course

Pdf Summary

A phase II clinical trial was conducted to evaluate the safety and efficacy of durvalumab as the first-line treatment for patients with advanced and metastatic non-small cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 2. The study aimed to understand the use of immunotherapy in NSCLC patients with borderline performance status.<br /><br />The trial included 50 patients with an ECOG PS of 2. The results showed that single-agent durvalumab was well-tolerated and safe in this patient population, with an encouraging overall survival benefit in patients with PD-L1 positive tumors. Most of the patients were treated at community-based clinics, making the results applicable to real-world settings.<br /><br />The study demonstrated that durvalumab monotherapy had an overall response rate of 26% in evaluable patients, with stable disease observed in 47% of patients. The median overall survival was 6 months for all patients and 11 months for patients with PD-L1 positive tumors.<br /><br />The study also assessed the treatment-related adverse events, with fatigue being the most common, occurring in 19% of patients. Grade 3 adverse events were infrequent, with only 2 patients experiencing grade 3 pneumonitis.<br /><br />The trial found that the health-related quality of life remained stable throughout the treatment cycles, based on the FACT-L questionnaire.<br /><br />In conclusion, the study demonstrated that durvalumab monotherapy is safe and effective as a first-line treatment for advanced NSCLC patients with an ECOG PS of 2. The results have real-world applicability and show that clinical trials can be conducted successfully in community settings.

Asset Subtitle

Khvaramze Shaverdashvili

Meta Tag

Speaker Khvaramze Shaverdashvili

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

phase II clinical trial

durvalumab

first-line treatment

advanced non-small cell lung cancer

metastatic NSCLC

Eastern Cooperative Oncology Group performance status

immunotherapy

PD-L1 positive tumors

overall survival

treatment-related adverse events